Harmony Biosciences Holdings (HRMY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Harmony Biosciences Holdings (HRMY) is Moderate Outperform.

The composite score behind that read is +0.21, weighing +0.44 of bullish evidence against -0.16 bearish.

Harmony Biosciences Holdings last closed at $40.28, +1.72% on the session.

Against the IVW growth benchmark the position is +0.92% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 47%.

4 graded predictions for HRMY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Harmony Biosciences Holdings in the 71st percentile on valuation and the 80th percentile on return on equity, where 100 is best.

Harmony Biosciences Holdings is classified under Health Care / Pharmaceuticals, with a market capitalisation of $2.31B.

StockMap tracks Harmony Biosciences Holdings as the 37th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Harmony Biosciences Holdings ranks 13th of 151 in the group, against a group median of -0.08.